Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study

Jane Griffin, Sally Lee, Maria Caiado, Steven Kesten, David Brendan Price

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

AIMS: To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD. METHODS: Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated. RESULTS: 4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64-0.85; p=0.0086) for exacerbations and 0.57 (0.46-0.70; p=0.004) for COPD-related referrals/hospitalisations. CONCLUSIONS: Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.
Original languageEnglish
Pages (from-to)104-110
Number of pages7
JournalPrimary Care Respiratory Journal
Volume17
Issue number2
Early online date2 Apr 2008
DOIs
Publication statusPublished - 1 Jun 2008

Fingerprint

Ipratropium
Albuterol
General Practice
Chronic Obstructive Pulmonary Disease
Databases
Research
Propensity Score
Referral and Consultation
Therapeutics
Hospitalization
Confidence Intervals
Incidence
Cholinergic Antagonists
Tiotropium Bromide

Keywords

  • Aged
  • Albuterol
  • Bronchodilator Agents
  • Databases, Factual
  • Family Practice
  • Female
  • Follow-Up Studies
  • Great Britain
  • Hospitalization
  • Humans
  • Ipratropium
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive
  • Referral and Consultation
  • Retrospective Studies
  • Scopolamine Derivatives
  • Treatment Outcome
  • COPD
  • General Practice Database
  • Hospitalisation
  • Ipratropium/Salbutamol
  • Tiotropium

Cite this

Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD : a UK General Practice Research Database 12-month follow-up study. / Griffin, Jane; Lee, Sally; Caiado, Maria; Kesten, Steven; Price, David Brendan.

In: Primary Care Respiratory Journal, Vol. 17, No. 2, 01.06.2008, p. 104-110.

Research output: Contribution to journalArticle

@article{62cc54869c2f481fa7510f4bd833e44e,
title = "Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study",
abstract = "AIMS: To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD. METHODS: Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95{\%} confidence intervals during a 12-month follow-up period were estimated. RESULTS: 4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95{\%} confidence intervals) were 0.74 (0.64-0.85; p=0.0086) for exacerbations and 0.57 (0.46-0.70; p=0.004) for COPD-related referrals/hospitalisations. CONCLUSIONS: Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.",
keywords = "Aged, Albuterol, Bronchodilator Agents, Databases, Factual, Family Practice, Female, Follow-Up Studies, Great Britain, Hospitalization, Humans, Ipratropium, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Referral and Consultation, Retrospective Studies, Scopolamine Derivatives, Treatment Outcome, COPD , General Practice Database, Hospitalisation, Ipratropium/Salbutamol, Tiotropium",
author = "Jane Griffin and Sally Lee and Maria Caiado and Steven Kesten and Price, {David Brendan}",
year = "2008",
month = "6",
day = "1",
doi = "10.3132/pcrj.2008.00024",
language = "English",
volume = "17",
pages = "104--110",
journal = "Primary Care Respiratory Journal",
issn = "1471-4418",
publisher = "Primary Care Respiratory Society UK",
number = "2",

}

TY - JOUR

T1 - Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD

T2 - a UK General Practice Research Database 12-month follow-up study

AU - Griffin, Jane

AU - Lee, Sally

AU - Caiado, Maria

AU - Kesten, Steven

AU - Price, David Brendan

PY - 2008/6/1

Y1 - 2008/6/1

N2 - AIMS: To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD. METHODS: Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated. RESULTS: 4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64-0.85; p=0.0086) for exacerbations and 0.57 (0.46-0.70; p=0.004) for COPD-related referrals/hospitalisations. CONCLUSIONS: Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.

AB - AIMS: To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD. METHODS: Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated. RESULTS: 4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64-0.85; p=0.0086) for exacerbations and 0.57 (0.46-0.70; p=0.004) for COPD-related referrals/hospitalisations. CONCLUSIONS: Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.

KW - Aged

KW - Albuterol

KW - Bronchodilator Agents

KW - Databases, Factual

KW - Family Practice

KW - Female

KW - Follow-Up Studies

KW - Great Britain

KW - Hospitalization

KW - Humans

KW - Ipratropium

KW - Male

KW - Middle Aged

KW - Pulmonary Disease, Chronic Obstructive

KW - Referral and Consultation

KW - Retrospective Studies

KW - Scopolamine Derivatives

KW - Treatment Outcome

KW - COPD

KW - General Practice Database

KW - Hospitalisation

KW - Ipratropium/Salbutamol

KW - Tiotropium

U2 - 10.3132/pcrj.2008.00024

DO - 10.3132/pcrj.2008.00024

M3 - Article

VL - 17

SP - 104

EP - 110

JO - Primary Care Respiratory Journal

JF - Primary Care Respiratory Journal

SN - 1471-4418

IS - 2

ER -